Atea Pharmaceuticals

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Atea Pharmaceuticals advances COVID-19 treatment, diversifies programs for growth

Atea Pharmaceuticals showcased strong performance in clinical development and financial stability, with a focus on addressing COVID-19 therapy limitations.
While challenges exist in deprioritizing the Dengue program, opportunities in other antiviral programs and strategic shifts offer avenues for growth.
The company's extended cash guidance to 2026 reflects adaptability to changing priorities and a commitment to long-term success.

Atea Pharmaceuticals excels in Q1 2023, poised for growth

Atea Pharmaceuticals demonstrated strong financial performance and progress in their COVID-19 and HCV programs in Q1 2023.
The company's robust cash balance, operational excellence, and promising drug profiles highlight their competitive position.
While facing challenges in regulatory environments and clinical trial execution, Atea has opportunities for growth and market expansion.
Overall, Atea Pharmaceuticals remains well-positioned for future success with a focus on innovation and strategic partnerships.

Atea Pharmaceuticals reports strong Q2 earnings, eyes growth in antiviral treatments

Atea Pharmaceuticals demonstrated financial stability and progress in their antiviral programs, particularly in COVID-19 and hepatitis C treatments. While challenges with COVID-19 mutations persist, the company's focus on innovative treatments and potential partnerships signal a promising future in the antiviral market.

Atea Pharmaceuticals excels in antiviral programs, eyes multibillion-dollar market

Atea Pharmaceuticals demonstrated strong performance in Q3 2023, leveraging their expertise in antiviral therapeutics to address critical healthcare challenges. While challenges such as trial enrollment and market competition exist, the company is well-positioned to capitalize on the growing demand for innovative antiviral treatments.

Atea Pharmaceuticals excels in drug development, eyes growth opportunities

Atea Pharmaceuticals is making significant strides in drug development, particularly in COVID-19 and HCV programs. With a strong financial position and a focus on addressing unmet medical needs, the company is poised for future growth and success.

Atea Pharmaceuticals reports robust Q1 earnings, highlights bemnifosbuvir potential

Atea Pharmaceuticals showcased strong financial stability and promising developments in its COVID-19 and HCV programs during the Q1 2024 earnings call. While facing challenges in trial enrollments and regulatory pathways, the company remains well-positioned to capitalize on market opportunities and deliver value through innovative treatments.

Atea Pharmaceuticals reports strong Q2 earnings and advances HCV treatments

Atea Pharmaceuticals is well-positioned with strong operational performance, a promising HCV treatment pipeline, and a solid financial foundation. Navigating industry competition and successfully advancing Phase III trials will be key challenges, but the company has opportunities to solidify its position as a leader in HCV treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.

Atea Pharmaceuticals Added to the Nasdaq Biotechnology Index

Responding to the rapidly evolving SARS-CoV-2, emerging variants and changing treatment landscape, Atea is updating the development strategy for AT-527

Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19

Investors need to pay close attention to Atea (AVIR) stock based on the movements in the options market lately.

Implied Volatility Surging for Atea (AVIR) Stock Options

Atea Pharmaceuticals Inc. ( AVIR , Financial) is a Boston-based clinical stage biotech company which became public in November of 2020 and quickly raised over $300 million cash.

Atea Pharmaceuticals - Boom and Bust in Biotechland

Roche calls it quits on the duo's attempt to develop an oral COVID-19 therapy.

Why Atea Pharmaceuticals Stock Is Sinking Today

The stock price of Atea Pharmaceuticals Inc (NASDAQ: AVIR) fell by over 10% pre-market today. This is why it happened.

Atea Pharmaceuticals (AVIR): Why The Price Fell Today

Atea to lead global clinical trial development of AT-527 and regain ex-US commercial rights Atea to lead global clinical trial development of AT-527 and regain ex-US commercial rights

Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche

Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q3 2021 Results - Earnings Call Transcript

Phase 3 MORNINGSKY Protocol Amendment to Include New Primary Endpoint, Refined Patient Population and Increased Dose, with Plan to Accelerate Completion of Enrollment

Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, November 11, 2021 at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2021, and to provide a clinical and corporate update.

Atea Pharmaceuticals to Host Third Quarter Financial Results Conference Call on November 11, 2021

If its coronavirus pill project can't be salvaged, it'll be trouble for investors.

Is There Any Hope for Atea Pharmaceuticals Stock?

Novavax

Omeros

Each for reasons of their own, Atea Pharmaceuticals, Omeros, and Novavax have had a very tough time this year.

3 Beaten-Down Biotech Stocks -- Can They Recover?

Johnson & Johnson

Ghosts, goblins, ghouls? No, it's three vaccine stocks.

3 Top COVID Stocks -- Are They Tricks or Treats?

Were warning signs there for investors all along?

Was Atea Pharmaceutical's Flop Predictable?

Vinco Ventures

Last week, the five biggest stock market losers declined between about 75% and 37%. Below is a look at each stock and what they may have in the cards going forward.

How The Future Looks For Last Week's Biggest Losers: Vinco Ventures, Atea Pharmaceuticals And More

Agenus

Ocular Therapeutix

Biotech stocks that fall hard on bad news can rebound in a flash.

Are Atea Pharmaceuticals, Agenus, Novavax, and Ocular Therapeutix Bad News Buy?

A mid-stage trial miss caused investors to hit the exits this week.

Why Atea Pharmaceuticals Stock Got Crushed This Week

Atea (AVIR) is developing an oral drug candidate, AT-527, as a potential treatment for COVID-19 in outpatients as well as hospitalized settings in several studies.

Atea (AVIR) Plunges on Oral COVID Candidate Study Failure

The stock price of Atea Pharmaceuticals Inc (NASDAQ: AVIR) fell by over 65% today. This is why it happened.

AVIR Stock: Why The Price Fell By Over 65% Today

The company's oral COVID-19 treatment looks like a dud in the mild-to-moderate COVID-19 setting.

Why Atea Pharmaceuticals Is Imploding Today

Atea Pharmaceuticals (AVIR) stock is on the move Tuesday after providing an update from its Phase 2 Moonsong clinical trial update. The post AVIR Stock: The Oral Covid-19 Therapy News That Has Atea Pharmaceuticals Plunging Today appeared first on InvestorPlace.

AVIR Stock: The Oral Covid-19 Therapy News That Has Atea Pharmaceuticals Plunging Today

Atea Pharmaceuticals Inc (NASDAQ:AVIR) stock is crashing today, down 72.2% to trade at $11.26 at last check, after the pharma company failed to meet the main goal in a mid-stage trial of its oral Covid-19 drug, AT-527.

Pharma Stock Plunges to Record Lows on Trial Data

Shares of Atea Pharmaceuticals Inc. AVIR, -68.50% took a 70.7% nosedive on heavy volume toward a record low in morning trading Tuesday, after the biopharmaceutical company said a Phase 2 trial of its oral treatment of SARS-CoV-2 virus in an outpatient setting failed to meet its primary endpoint. Trading volume swelled to 21.6 million shares, compared with the full-day average of about 2.7 million shares.

Atea Pharmaceuticals stock rocked after disappointing trial results of SARS-CoV-2 pill

(Reuters) -A mid-stage trial testing Atea Pharmaceuticals' COVID-19 treatment failed to meet the main goal of reducing the amount of SARS-CoV-2 virus in non-hospitalized patients with mild or moderate disease, the company said on Tuesday.

Atea Pharma's COVID-19 treatment fails to meet study goal; shares plunge

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate COVID-19. Related:   Atea Unveils Trial Amendments, New Data For COVID-19 Program.

News for Atea Pharmaceuticals Stock (AVIR)